A Study to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

TerminadoFase 2ClinicalTrials.gov

ID: NCT05727878Tipo: INTERVENTIONALInicio: 7 de feb de 2023Fin estimado: 19 de oct de 2025

Traducción no disponible, mostrando original

Resumen

The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.

Descripción detallada

Approximately 90 participants diagnosed with persistent corneal epithelial defect (PCED) will be enrolled at multiple US centers in a study to assess the safety and efficacy of KPI-012, a topical mesenchymal stem cell secretome therapy. After an initial cohort of at least 2 participants to evaluate the safety of the high strength product, participants in the second cohort will be randomized to treatment with either the product or vehicle (placebo) for 8 weeks. The percentage of healing will be compared between groups treated with product and vehicle. Total length of study participation will be approximately 34 weeks.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Have PCED for at least 7 days prior due to an underlying condition such as diabetic keratopathy, herpetic eye disease, severe dry eye disease, limbal stem cell deficiency, infectious keratitis, neurotrophic keratitis, post ocular surgery, medical trauma, chemical burn, etc.
PCED measurements meet study criteria.

Criterios de exclusión

Any active ocular infection or any active infectious disease that could impact the PCED.
Severe corneal burns in the Study Eye.
Severe limbal stem cell deficiency in either eye.
The circumference affected by limbal blood vessel ischemia greater than 75% of the circumference in the Study Eye.
Severe blepharitis or severe meibomian gland disease.
Severe eyelid abnormalities in the Study Eye, contributory to the persistence of the PCED.
Evidence of corneal ulceration.
Anticipated need for punctal occlusion.
Use of Oxervate in the Study Eye within past 30 days.
History of any surgical procedure for treatment of the study PCED.
History of any other ocular surgery in the Study Eye within 90 days prior to screening.
Not willing to suspend use of contact lens in the Study Eye.
Any use of Botox injections to induce pharmacologic blepharoptosis in the 90 days.
Expected use of systemic doxycycline.
Any use of chemotherapeutic agents within 7 days prior to Study, or anticipated use during the study.
History of current drug or alcohol abuse or addiction.
Use of another investigational agent within 30 days.
Participants who are pregnant, breastfeeding, or planning a pregnancy during the study.

Intervenciones

drug

KPI-012

KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells

drug

KPI-012 Vehicle

KPI-012 formulation with no active drug

Ubicaciones

Principal Investigator

Caba, Buenos Aires, Argentina

Principal Investigator

Rosario, Santa Fe Province, Argentina

Patrocinadores

PrincipalCombangio, Inc

ColaboradorKala Pharmaceuticals, Inc.

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Study to Evaluate Safety and Efficacy of KPI-012 Ophtha... | EligiMed